Correspondence: JoAnn Sperl-Hillen, MD, HealthPartners Research Foundation, 8170 33rd Ave S, MS 21111R, Minneapolis, MN 55440 (joann.m.sperlhillen@healthpartners.com).
Accepted for Publication: June 23, 2011.
Published Online: October 10, 2011. doi:10.1001/archinternmed.2011.507
Author Contributions: Drs Sperl-Hillen and Beaton had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Sperl-Hillen, Beaton, Parker, and Spain. Acquisition of data: Fernandes, Von Worley, Hanson, and Parsons. Analysis and interpretation of data: Sperl-Hillen, Beaton, Fernandes, Von Worley, Vazquez-Benitez, Parker, Hanson, Lavin-Tompkins, Glasrud, Davis, Adams, Parsons, and Spain. Drafting of the manuscript: Sperl-Hillen, Beaton, and Parker. Critical revision of the manuscript for important intellectual content: Sperl-Hillen, Beaton, Fernandes, Von Worley, Vazquez-Benitez, Parker, Hanson, Lavin-Tompkins, Glasrud, Davis, Adams, Parsons, and Spain. Statistical analysis: Sperl-Hillen, Beaton, Vazquez-Benitez, Parker, Hanson, Davis, Adams, and Parsons. Obtained funding: Sperl-Hillen, Beaton, and Spain. Administrative, technical, and material support: Fernandes, Von Worley, Hanson, Lavin-Tompkins, Glasrud, and Spain. Study supervision: Sperl-Hillen and Beaton.
Financial Disclosure: Dr Sperl-Hillen has received research support administered through HealthPartners Research Foundation for clinical trials from Merck and Co Inc, GlaxoSmithKline, Lilly, and Merck-ScheringPlough Pharmaceuticals. Drs Beaton, Davis, and Parsons and Mss Von Worley and Glasrud have received research support administered through a subcontract between LCF Research and HealthPartners Research Foundation (as a result of the primary contract between HealthPartners Research Foundation and Merck and Co Inc). Mr Fernandes, Drs Vazquez-Benitez, Parker, and Adams, and Mss Hanson and Lavin-Tompkins have received research support administered through HealthPartners Research Foundation from Merck and Co Inc. Dr Spain is a full-time employee of and owns stock in Merck and Co Inc.
Funding/Support: This study was funded by Merck and Co Inc, North Wales, Pennsylvania.
Role of the Sponsors: The project has been observed from the beginning by project managers from Merck and Co Inc US Outcomes Research Division. The current project manager is C. Victor Spain, DVM, PhD, an author of this article. Dr Spain has been involved through phone meetings twice a month in the management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript. He has not been involved in the design and conduct of the study or in data collection.
Additional Contributions: We gratefully acknowledge the assistance and support of the ABQ Health Partners diabetes education staff in New Mexico and HealthPartners Diabetes Program in Minnesota for providing the study interventions to participants as well as participating in the Conversation Map training. We also thank Barbara Eichorst, MS, RD, CDE, for her help in providing training to the diabetes educators at both study sites. We thank Dorothy Baumer, MS, Maureen Busch, Colleen King, Dave Butani, Shelly Eudy, Jaime Sekenski, BS, and Louise Hillen, BA, for their contributions to programming, patient recruitment, and survey completion. In addition, we thank Jeremy Gleeson, MD, Patrick O’Connor, MD, MPH, for their valuable consultative roles and support of the study. Finally, we thank Mary VanBeusekom, BA, for her meticulous editing skills.